Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

M3554

Antibody-drug conjugate · Cytotoxic, directed at disialoganglioside GD2

Phase 1 Most advanced trial

What is M3554?

M3554 is an antibody-drug conjugate in which the anti-GD2 antibody dinutuximab is linked by a cleavable linker to exatecan, a topoisomerase 1 inhibitor. The antibody binds GD2 on tumor cells, and after internalization the released exatecan inhibits DNA replication and induces apoptosis. It is being studied in advanced solid tumors, including soft tissue sarcoma and glioblastoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Antibody-drug conjugate
Targets
disialoganglioside GD2, DNA topoisomerase 1 (TOP1) (secondary target)
Mechanism
Cytotoxic, directed at disialoganglioside GD2
Pathways
DNA replication inhibition, cell cycle arrest, apoptosis
Therapy area
Oncology
In trials of
MRK
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

Conditions studied

Advanced Solid Tumor

Sources

Updated Nov 8, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.